Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Vaccine ; 33(26): 2990-6, 2015 Jun 12.
Article in English | MEDLINE | ID: mdl-25930115

ABSTRACT

The U.S. Department of Defense vaccinates personnel deployed to high-risk areas with the vaccinia virus (VACV)-based smallpox vaccine. Autoinoculations and secondary and tertiary transmissions due to VACV shedding from the vaccination site continue to occur despite education of vaccinees on the risks of such infections. The objectives of this study were to investigate, in naïve smallpox vaccinees, (a) whether the vaccination site can remain contagious after the scab separates and (b) whether the application of povidone iodine ointment (PIO) to the vaccination site inactivates VACV without affecting the immune response. These objectives were tested in 60 individuals scheduled to receive smallpox vaccine. Thirty individuals (control) did not receive PIO; 30 subjects (treatment) received PIO starting on post-vaccination day 7. Counter to current dogma, this study showed that VACV continues to shed from the vaccination site after the scab separates. Overall viral shedding levels in the PIO group were significantly lower than those in the control group (p=0.0045), and PIO significantly reduced the duration of viral shedding (median duration 14.5 days and 21 days in the PIO and control groups, respectively; p=0.0444). At least 10% of control subjects continued to shed VACV at day 28, and 3.4% continued to shed the virus at day 42. PIO reduced the proportion of subjects shedding virus from the vaccination site from day 8 until days 21-23 compared with control subjects. Groups did not differ significantly in the proportion of subjects mounting an immune response, as measured by neutralizing antibodies, IgM, IgG, and interferon-gamma enzyme-linked immunospot assay. When applied to the vaccination site starting on day 7, PIO reduced viral shedding without altering the immune response. The use of PIO in addition to a semipermeable dressing may reduce the rates of autoinoculation and contact transmission originating from the vaccination site in smallpox-vaccinated individuals.


Subject(s)
Military Personnel , Povidone-Iodine/administration & dosage , Smallpox Vaccine/administration & dosage , Smallpox Vaccine/immunology , Vaccinia virus/physiology , Vaccinia/prevention & control , Virus Shedding , Adult , Anti-Infective Agents, Local/administration & dosage , Antibodies, Neutralizing/blood , Antibodies, Neutralizing/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Enzyme-Linked Immunospot Assay , Female , Humans , Immunity, Cellular , Interferon-gamma/blood , Interferon-gamma/immunology , Male , Skin/virology , Smallpox/immunology , Smallpox/prevention & control , United States , Vaccination , Vaccinia/transmission , Vaccinia virus/immunology , Young Adult
3.
US Army Med Dep J ; : 7-18, 2013.
Article in English | MEDLINE | ID: mdl-23584903

ABSTRACT

In its 15th year, the Global Emerging Infections Surveillance and Response System (GEIS) continued to make significant contributions to global public health and emerging infectious disease surveillance worldwide. As a division of the US Department of Defense's Armed Forces Health Surveillance Center since 2008, GEIS coordinated a network of surveillance and response activities through collaborations with 33 partners in 76 countries. The GEIS was involved in 73 outbreak responses in fiscal year 2011. Significant laboratory capacity-building initiatives were undertaken with 53 foreign health, agriculture and/or defense ministries, as well as with other US government entities and international institutions, including support for numerous national influenza centers. Equally important, a variety of epidemiologic training endeavors reached over 4,500 individuals in 96 countries. Collectively, these activities enhanced the ability of partner countries and the US military to make decisions about biological threats and design programs to protect global public health as well as global health security.


Subject(s)
Communicable Disease Control/organization & administration , Communicable Diseases, Emerging/epidemiology , Disease Outbreaks , Global Health , Military Medicine/organization & administration , Sentinel Surveillance , Capacity Building , Humans , Laboratories , Organizational Objectives , Prevalence , United States , United States Department of Defense
SELECTION OF CITATIONS
SEARCH DETAIL
...